PFE Jun 2024 75.000 put
| Previous close | 45.90 |
| Open | 45.90 |
| Bid | 47.65 |
| Ask | 48.50 |
| Strike | 75.00 |
| Expiry date | 2024-06-21 |
| Day's range | 45.90 - 45.90 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
UPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, which can cause spontaneous as well as severe bleeding following injuries or surgery.
Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
The FDA approved Pfizer's hemophilia gene therapy on Friday, putting the pharma giant on track to rival the world's most expensive drug.
Business WireU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK, April 26, 2024--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var)
